查詢結果分析
相關文獻
- Lorcaserin用於肥胖治療
- 肥胖是否為傳染病
- The Effectiveness of Dietary Instruction in Obese School Children of Southern Taiwan
- 肥胖婦女減重前後體組成及熱量代謝之變化
- 青少年肥胖問題之探討
- Surgical Treatment of Morbid Obesity with Vertical Banded Gastroplasty: A Comparison between TA90-4.8 and TA90-B
- 肥胖兒童的脂質代謝
- 臺中市學童肥胖盛行率之分析:不同篩選指標的比較
- 肥胖婦女減重對其與常見代謝疾病相關之血中指標之影響
- 臺中市學齡兒童肥胖症與父母親體型相關性之研究
頁籤選單縮合
題 名 | Lorcaserin用於肥胖治療=Lorcaserin in Management of Obesity |
---|---|
作 者 | 邵時傑; 龍美雲; 石博仁; 陳柏璋; | 書刊名 | 藥學雜誌 |
卷 期 | 29:3=116 2013.09[民102.09] |
頁 次 | 頁38-42 |
分類號 | 418.21 |
關鍵詞 | 肥胖; 血清素受體作用劑; Lorcaserin; |
語 文 | 中文(Chinese) |
中文摘要 | 肥胖盛行率逐漸增加,並會造成許多慢性病。許多藥物曾上市用於肥胖治療,但卻因安全性考量先後下市。過去僅有 orlistat 為長期肥胖治療藥品,2012年美國 FDA (Food Drug Administration) 核准 lorcaserin 上市,建議使用於 BMI ≥ 30 kg/m2 (肥胖) 或 ≥ 27 kg/m2 (過重) 且至少有一項肥胖相關共病症 (包含高血壓、第二型糖尿病或血脂異常) 的成人,搭配飲食控制與運動的長期藥物治療。本文將淺談 lorcaserin 臨床試驗結果與藥物資訊,以供醫療人員參考。 |
英文摘要 | Prevalence of obesity has increased gradually, and it will cause lots of chronic diseases. Some drugs used to treat obesity before, but they were voluntarily withdrawn from the market. There was only orlistat indicated for long-term management for obesity previously, and U.S FDA (Food and Drug Administration) approved lorcaserin into the market in 2012. Lorcaserin was indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus or dyslipidemia. This article will introduce the background knowledge and results of clinical trials about lorcaserin. |
本系統中英文摘要資訊取自各篇刊載內容。